https://biotechmorning.com/news/ipsen-two-acquisitions-one-week-rare-disease Biotech Morning en 2026-08-01T14:23:47.679Z Ipsen Just Spent $2.5 Billion in One Week. Here's What They're Chasing. https://biotechmorning.com/news/astrazeneca-cspc-kidney-disease-sirna-deal Biotech Morning en 2026-08-01T14:22:54.586Z AstraZeneca's $1.77B Bet on a Chinese Partner Nobody Expected https://biotechmorning.com/news/novo-inflammation-drug-trial-failure Biotech Morning en 2026-08-01T14:22:03.104Z Novo's Big Bet on Inflammation Just Went Up in Smoke https://biotechmorning.com/news/lilly-2-3-billion-ajax-jak-inhibitor-deal Biotech Morning en 2026-08-01T14:21:14.900Z Lilly Just Bet $2.3 Billion That a Failed Drug Class Deserves a Second Chance https://biotechmorning.com/news/legend-biotech-in-vivo-car-t-perfect-response-rate Biotech Morning en 2026-08-01T14:20:20.688Z Legend Biotech Just Went 6 for 6 With a CAR-T That Builds Itself https://biotechmorning.com/news/bms-15-billion-hengrui-china-deal Biotech Morning en 2026-08-01T14:19:27.039Z BMS Just Bet $15 Billion on China's Drug Pipeline https://biotechmorning.com/news/fda-precheck-manufacturing-pilot-fast-lane Biotech Morning en 2026-08-01T14:18:33.255Z The FDA Just Created a Secret Fast Lane for Drug Factories https://biotechmorning.com/news/pfizer-ritlecitinib-vitiligo-phase-3-results Biotech Morning en 2026-08-01T14:17:45.287Z Pfizer Just Found a Way to Bring Color Back https://biotechmorning.com/news/first-toddlers-eligible-crispr-gene-therapy Biotech Morning en 2026-08-01T14:16:54.868Z The First Toddlers Eligible for CRISPR Are Two Years Old https://biotechmorning.com/news/novartis-myricx-adc-acquisition Biotech Morning en 2026-08-01T14:16:00.968Z Novartis Just Paid $1.1 Billion for a Drug That's Never Been Tested in Humans https://biotechmorning.com/news/lilly-zepbound-vial-pricing-trick Biotech Morning en 2026-07-31T14:28:19.367Z Eli Lilly's Sneaky Pricing Trick That Could Change Who Gets Zepbound https://biotechmorning.com/news/ipsen-kartos-navtemadlin-myelofibrosis-deal Biotech Morning en 2026-07-31T14:27:26.719Z Ipsen's $1.75 Billion Bet on a Protein That Guards Cancer Cells https://biotechmorning.com/news/fda-real-time-clinical-trials-operation-trailblazer Biotech Morning en 2026-07-31T14:26:38.435Z The FDA Wants to Watch Your Clinical Trial Live https://biotechmorning.com/news/first-base-edited-human-embryo Biotech Morning en 2026-07-31T14:25:47.026Z Scientists Just Edited a Human Embryo Without Cutting Its DNA https://biotechmorning.com/news/biomarin-inozyme-phase-3-failure Biotech Morning en 2026-07-31T14:24:54.411Z BioMarin Paid $270M for a Drug That Can't Fix Bones https://biotechmorning.com/news/pharma-2-trillion-forecast-asterisk Biotech Morning en 2026-07-31T14:24:00.677Z Pharma's $2 Trillion Moonshot Has One Giant Asterisk https://biotechmorning.com/news/vera-therapeutics-trutakna-fda-approval-igan Biotech Morning en 2026-07-31T14:23:05.473Z The $425K-a-Year Kidney Drug That Just Got the Green Light https://biotechmorning.com/news/astrazeneca-2-billion-copd-merck-ohtuvayre-challenger Biotech Morning en 2026-07-31T14:22:13.040Z AstraZeneca Just Spent $2.1 Billion to Pick a Fight With Merck https://biotechmorning.com/news/bms-printing-money-clock-ticking Biotech Morning en 2026-07-31T14:21:26.425Z BMS Is Printing Money Right Now. The Clock Is Ticking. https://biotechmorning.com/news/non-viral-car-t-tcx-001-first-in-human-trial Biotech Morning en 2026-07-31T14:20:30.483Z The CAR-T That Ditched Viruses Entirely https://biotechmorning.com/news/spudcell-synthetic-cell-built-from-scratch Biotech Morning en 2026-07-31T14:19:41.761Z Scientists Built a Cell From Scratch. It Eats, Grows, and Divides. But Is It Alive?